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Abstract
·AIM: To evaluate central macular thickness (CMT) and
mean choroidal thickness (MCT) in eyes with branch
retinal vein occlusion (BRVO), before and after
ranibizumab treatment using spectral domain -optical
coherence tomography (SD-OCT).
·METHODS: Forty -two patients with unilateral BRVO
and macular edema were included in this study. There
were 25 men and 17 women. Using SD -OCT, choroidal
thickness was measured at 500 滋m intervals up to 1500
滋m temporal and nasal to the fovea. MCT was calculated
based on the average of the 7 locations. All the eyes
with BRVO were treated with intravitreal ranibizumab
(0.5 mg/0.05 mL). Comparisons between the BRVO and
fellow eyes were analyzed using Mann-Whitney test . Pre-
injection and post-injection measurements were analyzed
using Wilcoxon test and repeated measure analysis.
· RESULTS: At baseline, there was a significant
difference between the BRVO and fellow eyes in MCT
[BRVO eyes 245 (165-330) 滋m, fellow eyes 229 (157-327) 滋m]
and CMT [BRVO eyes 463 (266-899) 滋m, fellow eyes 235
(148-378) 滋m (P=0.041, 0.0001, respectively)]. Following
treatment, CMT [295 (141-558) 滋m] and MCT [229 (157-
329) 滋m] decreased significantly compared to the
baseline measurements ( =0.001, 0.006, respectively).
Also BCVA (logMAR) improved significantly ( =0.0001) in
the BRVO eyes following treatment. After treatment CMT
[BRVO eyes 295 (141-558) 滋m, fellow eyes 234 (157-351) 滋m]
and MCT [BRVO eyes 229 (157-329) 滋m, fellow eyes 233
(162 -286) 滋m] values did not reveal any significant
difference in BRVO eyes and fellow eyes ( =0.051, 0.824,
respectively).
· CONCLUSION: In eyes with BRVO, CMT and MCT
values are greater than the fellow eyes, and decrease
significantly following ranibizumab injection.
· KEYWORDS: branch retinal vein occlusion; choroidal
thickness; macular edema; optical coherence tomography;
ranibizumab
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INTRODUCTION
R etinal vein occlusion (RVO) is one of the most frequentmajor retinal vascular disease after diabetic retinopathy[1].
Venous thrombus formation as a result of RVO and leads to
poor venous drainage, dilation and tortuosity of the large
retinal veins and increased retinal capillary pressure. These
changes result in exudation of blood, fluid, lipid into retina,
leading to macular edema [2]. Macular edema is a frequent
cause of visual loss that should be the main treatment target[3].
Treatment strategies for macular edema consist of focal laser
photocoagulation [4-5], intravitreal steroids [6], and injection of
anti-vascular endothelial growth factor (VEGF) protein
compounds [7-8]. Macular edema in patients with RVO seems
to be closely related to VEGF levels in the vitreous[9-10]. Thus,
inhibiting VEGF seems to be a reasonable therapeutic
approach[8,11].
The choroid is a highly vascular tissue that is directly
influenced by intraocular pressure as well as perfusion
pressure [12]. Choroidal blood flow is the highest of any tissue
in the body to satisfy the normal metabolic demands of the
outer retina [13]. RVO is accompanied with retinal hypoxia
which leads to increased VEGF expression in the retinal
pigment epithelium, pericytes and microvascular endothelial
cells [14]. VEGF induces vessel dilatation and increased ocular
blood flow through a mechanism involving nitric oxide
production, and is proposed to increase the choroidal
thickness[15].
The aim of this study was to compare the mean choroidal
thickness (MCT) and central macular thickness (CMT) in
eyes with branch retinal vein occlusion (BRVO) before and
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after the treatment with intravitreal ranibizumab, and
compare the results with the unaffected fellow eyes.
SUBJECTS AND METHODS
In this retrospectively designed cross-sectional study, the data
of consecutive patients with unilateral BRVO and macular
edema, who were diagnosed between January 2012 and June
2015, were evaluated. This study adhered to the tenets of
Decleration of Helsinki and was approved by the Baskent
University Institutional Review Board and Ethics Committee
(KA13/272).
The primary outcome measure was to evaluate the changes in
MCT and CMT, before and after intravitreal injection of
ranibizumab in patients with BRVO. Secondary outcome
measure was to compare these values with the normal fellow
eyes.
Ophtalmologic examination included best corrected visual
acuity (BCVA), slit lamp biomicroscopy, and retinal
examination, in addition to fundus fluorescein angiography
(FFA) and spectral domain-optical coherence tomography
(SD-OCT) examinations. The diagnosis of BRVO was
determined according to the clinical picture and FFA as
dilated and tortuous veins, flame-shaped hemorrhages, dot
and blot hemorrhages, retinal edema and cotton wool spots
affecting the part of the retina drained by the obstructed vein.
The BRVO eyes with macular edema, exceeding 250
microns were included in the study and compared with the
fellow eyes without any macular or retinal disease. The
exclusion criterias were any history of vitreous surgery,
intravitreal injection of either any anti-VEGF agent or
steroid, and findings of vitreo-macular traction or epiretinal
membrane, as well as macular edema due to any reason other
than BRVO. BRVO eyes were treated with 3 doses of
intravitreal injection of ranibizumab (Lucentis; Genentech;
San Francisco, CA, USA) (0.5 mg/0.05 mL) at one month
intervals.
Optical coherence tomography (OCT) measurements were
performed by the same experienced technician using a high
speed and high resolution SD-OCT device (姿=840 nm, 26 000
A-scans/s and 5 滋m axial resolution), Optovue RTVue
software V.3.5 (Optovue Inc., Fremont, California, USA).
Macular thickness analysis were performed by the MM5
(5伊5 mm2 grid of 11 horizontal and 11 vertical lines with 668
A-scans each and an inner 3伊3 mm2 grid of 6 horizontal and
6 vertical lines with 400 A-scans each). For choroidal
analysis, horizontal B-scan images centered on the fovea
were selected. Each B-scan image is constructed from a
number of line scans through the same retinal locations and
each line scan consists of 1024 A-scans. By automatically
inverting the image, the chorioretinal interface became
adjacent to zero delay. The retina cross-line scan has 32
frames averaged, 16 per direction without tracking[16].
The choroidal thickness was measured from the posterior
edge of the retinal pigment epithelium (RPE) to the
choroid-sclera junction at the fovea and at 500 滋m intervals
up to 1500 滋m temporal as well as nasal to the fovea at 7
locations (Figure 1). The MCT was calculated based on all 7
measurements for each eye (Figures 1, 2). Choroidal
thickness measurements were performed by two masked
physicians (Coban-Karatas M and Ulas B). The average of
two measurements was taken for the analysis. Also reliability
statistics for two examiners was performed. The BCVA (in
logMAR) and CMT as well as MCT measurements were
evaluated at baseline (zero visit) and 1mo following the third
intravitreal injection (follow-up visit), and the measurements
at each time point were compared.
Statistical Aanalysis Statistical analysis was performed
using the statistical package SPSS software (Statistical
Package for the Social Sciences, version 17.0, SPSS Inc,
Chicago, III, USA). For each continuous variable, normality
was checked by Kolmogorov Smirnov and Shapiro-Wilk tests
and by histograms. Comparisons between the eye with
BRVO and fellow eye were performed with Mann-Whitney
test for the data not normally distributed. Pre-injection
and post-injection measurements were analyzed using
Wilcoxon test. Values of less than 0.05 were considered
statistically significant. Reliability statistics and inter-
observer correlation was evaluated by Cronbach's alpha.
RESULTS
There were 42 patients with unilateral BRVO, with a mean
age of 59.2依7.5y (range 42 to 81y). Twenty-five (59.5%)
were male and 17 (40.5%) were female. Systemic disease
questioning revealed hypertension in 28 patients (66.7%) and
diabetes mellitus in 6 patients (14.3%). None of the patients
had retinopathy in the fellow eye.
Figure 1 Baseline choroidal thickness measurements of a
patient with BRVO.
Figure 2 Choroidal thickness measurements of a patient with
BRVO after intravitreal ranibizumab treatment.
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At the zero visit BCVA ranged from 2.0 to 0.2 (logMAR)
(median, 0.7), and at the follow-up visit it improved to 1.2 to
0.0 (logMAR) (median 0.4) ( =0.0001; Figure 3).
At the zero visit, the median (min-max) MCT was 245 滋m
(165-330 滋m) in BRVO eyes, and 229 滋m (157-327 滋m) in
the fellow eyes. The study eyes showed greater MCT
compared to the control eyes ( =0.041). Similarly, study
eyes showed greater CMT compared to the control eyes ( =
0.0001). The median (min-max) of CMT was 463 滋m
(266-899滋m) in the study eyes and 235 滋m (148-378 滋m) in
the control eyes (Table 1).
At the follow-up visit CMT and MCT improved significantly
in the study eyes ( =0.001, 0.006, respectively) compared
to the measurements at zero visit (Figures 4, 5). The median
(min-max) values for MCT was 229 滋m (157-329 滋m), and
for CMT was 295 滋m (141-558 滋m) at the follow-up visit.
There was no difference at the follow-up visit between the
study and the control eyes for CMT and MCT values ( =
0.051, 0.824 respectively) (Table 1). In the control eyes, also
no difference was found in CMT and MCT values at zero
visit and follow-up visit ( =0.861, 0.826 respectively).
The reliability statistics of two masked physicians were
evaluated by Cronbach's alpha (Cronbach's alpha=0.934,
Table 1 Comparison of median (minumum and maximum) values of eyes with BRVO and fellow eyes before and after 
treatment 
Study eye Control eye 
Measured data 
Med (min-max) 1P Med (min-max) 1P 
2P 
BCVA (zero visit) 0.7 (0.2-2.0) 0.1 (0.0-0.3) 0.0001 
BCVA (follow-up visit) 0.4 (0.0-1.2) 
0.0001 
0.1 (0.0-0.3) 
0.515 
0.0001 
CMT (zero visit) 463 (266-899) 235 (148-378) 0.0001 
CMT (follow-up visit) 295 (141-558) 
0.001 
234 (157-351) 
0.861 
0.051 
MCT (zero visit) 245 (165-330) 229 (157-327) 0.041 
MCT (follow-up visit) 229 (157-329) 
0.006 
233 (162-286) 
0.826 
0.824 
BCVA: Best corrected visual acuity; CMT: Central macular thickness; MCT: Mean choroidal thickness. 1Comparison between pre 
and post values using Wilcoxon test; 2Comparison of the eye with BRVO and fellow eye using Mann-Whitney U test. Values of P 
less than 0.05 were considered statistically significant. 
Figure 3 BCVA (LogMAR) improved significantly at the
follow-up visit in BRVO eyes.
Figure 4 CMT improved significantly at the follow-up visit in
BRVO eyes In the control eyes, no difference was found in CMT
values at zero visit and follow-up visit.
Figure 5 MCT improved significantly at the follow-up visit in
BRVO eyes In the control eyes, no difference was found in MCT
values at zero visit and follow-up visit.
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95% CI 0.90-0.05). Inter-observer correlation was higher
than 90%. The differences between the measurements of two
masked physicians were not more than 5%.
DISCUSSION
Until recently, the choroid could only be evaluated with
indocyanine green angiography[17-18], laser Doppler flowmetry[19]
and ultrasound[20]. Although, it is possible to diagnose choroid
vessel abnormalities and changes in the blood flow with these
techniques, SD-OCT enabled us to achieve 3-dimensional
anatomic information about RPE and choroid layers [21-22].
OCT is a noninvasive imaging modality used to acquire
high-resolution cross sectional scans of the retina. Recently,
Spaide [21] described a new acquisition technique,
namely enhanced depth imaging (EDI), using Spectralis OCT
device (Heidelberg Engineering, Heidelberg, Germany).
Herein, placing the acquired structures deeper close to zero
delay, allowed a better visualization of the choroid[21].
Due to increased interest in choroidal imaging with OCT,
other methods have been used to try to better visualize and
and measure the choroid, including use of swept-source
OCT [23] and longer wavelength OCT [24-25]. All of these
methods, however, potentially cause loss of clear
visualization of the retinal surface where other pathologies
such as vitreo-macular traction or epiretinal membrane might
be present and contributing to poor vision[26].
A high reliability and reproducibility of choroidal thickness
measurements across three SD-OCT systems (Cirrus
Spectralis, Cirrus RTVue, Spectralis RTVue) in normal
subjects [16]. Twenty-eight subjects of young healthy adults
with no retinal and choroidal pathology and normal vision
were analyzed. Choroidal thickness in normal eyes was
manually measured in 5 areas. Measurements from any pair
of three instruments were strongly correlated. There was
good reproducibility between choroidal thickness of images
acquired by Cirrus, Spectralis and RTVue[16].
In RTVue software "chorioretinal" mode achieves the same
purpose as EDI described by Spaide [21] with a slightly
different approach. RTVue's 'chorioretinal' mode moves the
zero delay closer to the choroid and achieves the same effect
as EDI without inverting the retinal image [27]. Using this
technique, we found that eyes with BRVO showed
significantly greater MCT and CMT compared to the fellow
control eyes before the treatment (zero visit). At the
follow-up visit (one month following the third injection)
CMT and MCT values improved in the BRVO eyes
compared to the zero visit measurements. In the control eyes,
however, no difference in CMT and MCT between zero and
follow-up visit was found. This could be explained by
increased expression of VEGF leading to increased thickness
of choroid in patients with BRVO.
Several studies focused on choroidal thickness measurements
in various diseases of the retina and choroid such as
Vogt-Koyanagi-Harada disease [28], polypoidal choroidal
vasculopathy [29] and central serous chorioretinopathy [30]. It
was demonstrated that choroidal thickness can be measured
by SD-OCT, and choroidal thickness disparity exists among
patients with the clinical diagnosis of wet and dry age-related
macular degeneration [12]. Imamura [30] reported that the
choroidal thickness in central serous chorioretinopathy was
significantly greater than the choroidal thickness in normal
eyes. EDI SD-OCT revealed a very thick choroid in patients
with central serous chorioretinopathy. This finding provides
additional evidence that central serous chorioretinopathy may
be caused by increased hydrostatic pressure in the choroid.
In a recent study, subfoveal choroidal thickness in patients
with central retinal vein occlusion (CRVO) using EDI OCT
was evaluated retrospectively. Thirty-six patients with
macular oedema were treated with intravitreal bevacizumab
(1.25 mg /0.05 mL). Mean subfoveal choroidal thickness after
intravitreal bevacizumab was 227.7 依65.1 滋m, which was
thinner than that before intravitreal bevacizumab therapy
(266.9依79.0 滋m; <0.01, paired test). Subfoveal choroidal
thickness of CRVO eyes was significantly greater than that of
fellow eyes and decreased significantly after intravitreal
bevacizumab treatment. Enhanced depth imaging optical
coherence tomography can be used to evaluate choroidal
involvement in CRVO and may assist noninvasive diagnosis
and management of this disease [31].
In the present study, with SD-OCT we demonstrated that
both MCT and CMT parameters were greater in BRVO
patients and decreased significantly after ranibizumab
treatment. Choroidal thickness significantly increases in eyes
with unilateral BRVO and can return to normal levels
following anti-VEGF treatment. This could be explained by
increased expression of VEGF leading to increased thickness
of choroid in patients with BRVO.
Being a retrospective study, with a small sample size are the
shortcomings of this study. However, we believe that our
results could be a sample for future studies on BRVO.
In conclusion, using the SD-OCT software, which enables the
measurement of choroidal thickness, this study demonstrated
that choroidal thickness in BRVO eyes with macular edema
was significantly greater than the fellow eyes and decreased
following the treatment with three doses of an anti-VEGF
agent (ranibizumab). According to our results, we believe
that SD-OCT is an effective non-invasive tool to evaluate the
choroid and detect choroidal changes in pathologic states
such as BRVO. Future studies with larger patient numbers
are needed to support our findings.
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